Studies have shown that bispecific ADCs targeting programmed death-ligand 1 (PD-L1) and B7 homolog 3 (B7-H3) not only deliver cytotoxic payloads to tumor cells with high selectivity but also activate the immune system through multiple mechanisms, including immune checkpoint inhibition and immunogenic cell death, thereby achieving more potent immunotherapeutic effects[9]. The gene discussed is CD276; the disease is neoplasm.